Comparison
GHK-Cu vs. Matrixyl
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Cosmetic
CAS no.
49557-75-7
214047-00-4
Molecular weight
340.4 g/mol
802.06 g/mol
Half-life
no data
no data
Sequence
GHKPalmitoyl-Lys-Thr-Thr-Lys-SerMechanism of action
GHK-Cu
Endogenous tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper(II) ions. In skin-cell models and skin biopsies an influence on collagen synthesis, antioxidant markers, gene-expression profiles and wound-healing processes has been described. In topical use in cosmetic studies, changes in various skin parameters have been reported.
Matrixyl
KTTKS is a fragment of the procollagen I sequence and appears to be part of a feedback mechanism in fibroblasts: elevated concentrations signal intact collagen synthesis and downregulate new synthesis, while low concentrations stimulate it. In cell-culture studies, stimulation of collagen types I/III, elastin, fibronectin and glycosaminoglycans has been documented. The palmitoyl modification is intended to improve skin penetration; effect at the site of action (dermal fibroblasts) depends on permeation.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
5
5
of which in humans
2
2
Effects recorded
4
3
Open conflicts
1
0
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between GHK-Cu and Matrixyl?
- GHK-Cu is classified as "Cosmetic", while Matrixyl is classified as "Cosmetic". GHK-Cu: Endogenous tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper(II) ions. Studied in skin models and small human trials on collagen synthesis, skin regeneration and wound healing; permitted as a cosmetic ingredient in the EU. Matrixyl: Synthetic pentapeptide (KTTKS) with a palmitoyl modification, marketed as a topical anti-aging ingredient (Lipotec/Sederma). Structurally derived from a collagen-I fragment; intended to stimulate fibroblast activity. Cosmetic ingredient, not a medicine. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, GHK-Cu or Matrixyl?
- The highest available evidence level is "Human trial" for GHK-Cu and "Human RCT" for Matrixyl. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of GHK-Cu and Matrixyl in Germany and the United States?
- Germany: GHK-Cu — Unapproved, Matrixyl — Unapproved. United States: GHK-Cu — Unapproved, Matrixyl — Unapproved. These are factual summaries with source and review date on the individual pages.